Phase I study of tomuzotuximab, a glycoengineered therapeutic antibody against the epidermal growth factor receptor, in patients with advanced carcinomas

BACKGROUND: Changes in glycosylation of the constant domain (Fc) of monoclonal antibodies (mAbs) enhance antibody-dependent cell-mediated cytotoxicity independently of downstream effects following receptor blockade by the antibody, thus extending their indication. We investigated the safety, pharmac...

Descripción completa

Detalles Bibliográficos
Autores principales: Fiedler, Walter, Cresta, Sara, Schulze-Bergkamen, Henning, De Dosso, Sara, Weidmann, Jens, Tessari, Anna, Baumeister, Hans, Danielczyk, Antje, Dietrich, Bruno, Goletz, Steffen, Zurlo, Alfredo, Salzberg, Marc, Sessa, Cristiana, Gianni, Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5812399/
https://www.ncbi.nlm.nih.gov/pubmed/29464112
http://dx.doi.org/10.1136/esmoopen-2017-000303

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5812399/
https://www.ncbi.nlm.nih.gov/pubmed/29464112
http://dx.doi.org/10.1136/esmoopen-2017-000303

Ejemplares similares